DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Prescription Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global anti-obesity prescription drugs market to grow with a CAGR of 4.97% over the forecast period of 2018-2024.
According to the study, the global anti-obesity prescription drugs market is promoted by factor such as rising cases of obesity worldwide, substantial rise in incidences of chronic diseases due to obesity and increased work load and stress. On the other hand a stringent regulation by the FDA is one of the restraining factors negatively affecting the growth in the market over the forecast period.
The report on anti-obesity prescription drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global anti-obesity prescription drugs market over the period of 2016 to 2024. Moreover, the report is collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global anti-obesity prescription drugs market over the period of 2016 to 2024. Further, the author's Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.
The global anti-obesity prescription drugs market is segmented on the basis of drug class, distribution channel and age group.
Global Anti-obesity Prescription Drugs Market by Drug Class
- Phentermine And Topiramate
- Bupropion And Naltrexone
Global Anti-obesity Prescription Drugs Market by Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Global Anti-obesity Prescription Drugs Market by Age Group
- F Hoffmann La Roche Ltd
- Orexigen Therapeutics, Inc
- Novo Nordisk A/S
- Arena Pharmaceuticals, Inc
- VIVUS, Inc
- Boehringer Ingelheim
For more information about this report visit https://www.researchandmarkets.com/research/vnxt43/antiobesity?w=4